HSCI and Natsimbio Holding, owned by Rostec, will create a combined vaccine to prevent coronavirus and influenza. The composition of the drug will include components against four strains of influenza viruses produced by Rostec and HSCI's patented vaccine platform. Clinical trials will begin in the 2nd half of 2022.

Human Stem Cell Institute's RAS net income for the 3 months of 2022 was ₽75.173 million, up 2.7 times from ₽27.773 million in the previous year. Revenue increased 72.3% to ₽29.675 million versus ₽17.227 million a year earlier.

Human Stem Cell Institute's IFRS net income for 2021 was ₽33.547 million, down 3 times from ₽103.404 billion in the previous year. Revenue rose 8.9% to ₽1.181 billion compared to ₽1.084 billion a year earlier.

HSCI entered into an investment agreement with Histograft, a company developing and introducing gene-activated materials for medical purposes. The total investment amount during 2022-2023 will be ₽50 million. HSCI also receives a controlling stake in Histograft.